Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines
Table 4
Correlations between clinicopathological characteristics and the status of TERTp mutations.
Total
IDH
value
MGMT
value
Mut
Wt
(%)
(%)
(%)
(%)
(%)
Sex
0.505
0.707
Male
84 (57.1)
41 (53.9)
43 (60.6)
63 (58.3)
21 (53.8)
Female
63 (42.9)
35 (46.1)
28 (39.4)
45 (41.7)
18 (46.2)
Age (years)
0.005
0.257
<45
70 (47.6)
42 (55.3)
28 (39.4)
50 (46.3)
20 (51.3)
45-60
59 (40.1)
31 (40.8)
28 (39.4)
47 (43.5)
12 (30.8)
≥60
18 (12.2)
3 (3.9)
15 (21.1)
11 (10.2)
7 (17.9)
Tumor location
<0.001
0.022
Frontal
91 (61.9)
58 (76.3)
33 (46.5)
73 (67.6)
18 (46.2)
Others
56 (38.1)
18 (23.7)
38 (53.5)
35 (32.4)
21 (53.8)
Histology
<0.001
0.009
DA
37 (25.2)
20 (26.3)
17 (23.9)
22 (20.4)
15 (38.5)
AA
15 (10.2)
6 (7.9)
9 (12.7)
14 (13.0)
1 (2.6)
AO
24 (16.3)
16 (21.1)
8 (11.3)
20 (18.5)
4 (10.3)
OA
6 (4.1)
4 (5.3)
2 (2.8)
2 (1.9)
4 (10.3)
O
28 (19.0)
22 (28.9)
6 (8.5)
24 (22.2)
4 (10.3)
GBMs
37 (25.2)
7 (9.2)
29 (40.8)
26 (24.1)
11 (28.2)
Pathologic stage
<0.001
0.286
Grade II-III
109 (74.1)
67 (88.2)
42 (59.2)
83 (76.1)
26 (66.7)
Grade IV
38 (25.9)
9 (11.8)
29 (40.8)
25 (22.9)
13 (33.3)
Ki-67
0.011
1.000
<15%
89 (60.5)
54 (71.1)
35 (49.3)
65 (60.2)
24 (61.5)
≥15%
58 (39.5)
22 (28.9)
36 (50.7)
43 (39.8)
15 (38.5)
MGMT promoter
0.003
—
Methylated
108 (73.5)
64 (84.2)
44 (62.0)
—
—
Unmethylated
39 (26.5)
12 (15.8)
27 (38.0)
—
—
TERT promoter
0.312
0.088
Mutation
59 (40.1)
34 (44.7)
25 (35.2)
48 (44.4)
11 (28.2)
Wild type
88 (59.9)
42 (55.3)
46 (64.8)
60 (55.6)
28 (71.8)
TERTp: the promoter region of the telomerase reverse transcriptase gene; IDH: isocitrate dehydrogenase; MGMT: O6-methylguanine-DNA methyltransferase; Mut: mutation; Wt: wild-type; M: methylated; U: unmethylated; DA: diffuse astrocytoma; AA: anaplastic astrocytoma; AO: anaplastic oligodendroglioma; OA: oligoastrocytoma; O: oligodendroglioma; GBMs: glioblastomas. value was calculated by the Pearson chi-square test or the 2-tailed Fisher’s exact test. Statistically significant: .
